Cadila Pharma unveils quadrivalent influenza vaccine Cadiflu Tetra

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-05 10:00 GMT   |   Update On 2024-03-20 10:53 GMT

New Delhi: Cadila Pharmaceuticals has said it has launched a vaccine to prevent influenza, a recurrent and widespread viral infection. The drug firm has introduced quadrivalent Cadiflu Tetra vaccine which has been approved by the DCGI (Drugs Controller General of India) for use in adults and children.

The new vaccine targets four strains of the influenza virus subtype -A and B, responsible for seasonal epidemics, the drug firm said in a statement.

Advertisement

Developed using proprietary technology employing nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material, it added.

"This breakthrough in vaccine development also holds promise for enhancing the protection of pregnant women against influenza, contributing to the overall well-being of both mother and child," Cadila Pharmaceuticals CMD Rajiv I Modi said.
Influenza, commonly known as seasonal flu, is a highly contagious acute respiratory illness caused by viruses.

Medical Dialogues team had earlier reported that Cadila Pharma has launched the world's first aqueous formulation of cholecalciferol for Vitamin D deficiency.

Located in Ahmedabad, Cadila Pharmaceuticals Ltd. develops and produces pharmaceutical products in India and sells and distributes them in over 100 countries. 
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News